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ABSTRACT Pharmacodynamics of a polymyxin B, meropenem, and rifampin triple com-
bination were examined against Klebsiella pneumoniae carbapenemase-producing Kleb-
siella pneumoniae (KPC-Kp) ST258. In time-kill experiments against three KPC-Kp isolates,
triple combination generated 8.14, 8.19, and 8.29 log10 CFU/ml reductions within 24 h.
In the hollow-fiber infection model, the triple combination caused maximal killing of
5.16 log10 CFU/ml at 78 h and the time required for regrowth was more than doubled
versus the 2-drug combinations. Remarkably, combinations with a high single-dose poly-
myxin B burst plus rifampin preserved KPC-Kp polymyxin susceptibility (MIC240 h  0.5
mg/liter) versus the same combination with traditionally dosed polymyxin B, where re-
sistance was amplified (MIC240 h  32 mg/liter).
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Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp)strains have spread worldwide and are associated with unacceptable mortality
rates of up to 50% in the hospital setting (1, 2). The ST258 lineage of KPC-Kp is the most
common clone globally and in the United States (3). The genes encoding KPC enzymes
are commonly found on plasmids or transposons that contain additional antibiotic
resistance determinants, resulting in multidrug-resistant (MDR) isolates susceptible to
only a few preserved antimicrobial agents (4).
Although the polymyxin antibiotics (polymyxin E [colistin] and polymyxin B) fell
out of favor after their introduction in the 1950s due to concerns over dose-limiting
toxicities, their clinical use has seen a recent resurgence given the sharp rise in
infections caused by MDR Gram-negative pathogens. In many clinical scenarios,
polymyxin B is favored over colistin due its more favorable pharmacological prop-
erties that can be attributed to its administration as an active antibiotic. The
polymyxins are among the only remaining classes of antibiotics that consistently
maintain activity against KPC-Kp, with susceptibility rates of 85% (5). Despite
sustained in vitro activity, treatment with polymyxin monotherapy frequently re-
sults in clinical failure, probably due to rapid proliferation of resistant subpopula-
tions (6, 7). Polymyxin-carbapenem combination regimens have been associated
with improved clinical outcomes and reduced mortality in KPC-Kp infections,
providing a viable alternative to polymyxin monotherapy (8, 9). However, the
clinical benefit of adding a carbapenem to the polymyxin is not apparent in
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infections due to KPC-Kp with elevated carbapenem MICs (16 mg/liter) (10).
Interestingly, rifampin-containing combination regimens to combat KPC-Kp have
shown promise in preclinical animal models and some in vitro studies (11–13).
However, optimized combination regimens involving polymyxins, carbapenems,
and rifampin have yet to be fully elucidated. Here, we describe the pharmacodynamic
activity of single-drug regimens and double- and triple-drug combination regimens con-
taining polymyxin B, meropenem, and rifampin against KPC-2-producing K. pneumoniae
ST258 isolates with elevatedmeropenemMICs. To our knowledge, this study represents the
first to have examined humanized polymyxin and polymyxin-based combination regimens
over 10 days in the hollow-fiber infection model (HFIM) against KPC-Kp with high mero-
penem MICs.
Polymyxin B (Sigma-Aldrich, St. Louis, MO; lot WXBB4470V), meropenem (AK
Scientific, Union City, CA; lot LC24337), and rifampin (Sigma-Aldrich, St. Louis, MO;
lot 109K1417) were utilized in all experiments, and MICs were determined in
duplicate using broth microdilution according to CLSI guidelines (14). The KPC-2-
producing K. pneumoniae ST258 bloodstream isolates used in the present study
(KPC-Kp 9A, KPC-Kp 24A, and KPC-Kp 27A) were obtained from cultures of blood
from three different patients with hematologic malignancies, all of whom devel-
oped septic shock and died within 1 week of bacteremia onset (15). The KPC-Kp
isolates were subjected to PCR with previously published primers for detection of
blaSHV, blaTEM, blaCTX-M, blaNDM, blaVIM, blaIMP, and blaOXA-48 genes, followed by
sequencing of positive results (16, 17). The presence and type of blaKPC gene were
determined by a multiplex molecular-beacon real-time PCR assay (18), and PCR was
TABLE 1 KPC-Kp isolate characteristics, including -lactamases and MIC values, followed by the antibiotic regimens used in the time-kill
experiments and mean changes in bacterial log10 CFU/ml from baseline after 4, 8, and 24 ha
KPC-Kp
isolate -Lactamase(s)
MIC (mg/liter)
Time-kill experiment
antimicrobial(s)b,c
Time-kill experiment  bacterial log10 CFU/ml  SDd,e
PMB MERO RIF 4 h 8 h 24 h
9A KPC-2, SHV-11, TEM-1 0.5 16 64 PMB 2.41 2.93 0.45 0.54 0.09 0.86 0.04
PMB 6 4.19 0.49 2.20 0.15 0.82 0.02
PMB 2.41  MERO 3.73 0.05 0.67 0.16 0.89 0.05
PMB 2.41  RIF 3.16 0.18 3.78  1.73 0.98 0.22*
PMB 6  MERO 4.87 0.04 3.51 0.78 0.82 0.12
PMB 6  RIF 5.87 3.20 4.73  1.55 5.06  0.26*
PMB 2.41  MERO  RIF 3.19 0.19 5.81  0.44* 6.75  1.91
PMB 6  MERO  RIF 8.13  0.01 8.13  0.01* 8.13  0.01*
24A KPC-2 0.5 64 64 PMB 2.41 0.55 0.97 0.06 0.75 0.90 0.20
PMB 6 5.85 0.64 4.32 0.78 0.28 1.03
PMB 2.41  MERO 0.98 1.25 0.15 0.81 0.91 0.14
PMB 2.41  RIF 3.27  0.28 3.16  0.44 0.70 0.17
PMB 6  MERO 6.11 0.69 4.28 0.99 0.33 1.22
PMB 6  RIF 8.15  0.06 8.15  0.06 7.05  1.50*
PMB 2.41  MERO  RIF 3.87  0.40 3.59  0.44* 0.70 0.12
PMB 6  MERO  RIF 8.23  0.06 8.23  0.06 8.23  0.06
27A KPC-2, SHV-11, TEM-1 1 32 64 PMB 2.41 3.34 0.87 1.06 0.57 0.74 0.03
PMB 6 5.14 0.62 3.81 0.96 0.20 0.56
PMB 2.41  MERO 3.37 0.47 1.42 0.20 0.75 0.05
PMB 2.41  RIF 0.93 0.27 1.20 0.50 0.46 0.47
PMB 6  MERO 5.62 0.21 5.40 0.18 3.57  2.74
PMB 6  RIF 2.78 0.22 4.14 0.60 3.92  0.25*
PMB 2.41  MERO  RIF 1.34 0.09 1.43 0.23 1.25 0.21*
PMB 6  MERO  RIF 2.92 0.53 4.36 0.75 8.24  0.07*
aBaseline, 0 h.
bPMB 2.41, polymyxin B at 2.41 mg/liter; PMB 6, polymyxin B at 6 mg/liter; MERO, meropenem at 49.6 mg/liter; RIF, rifampin at 3.5 mg/liter.
cThe MERO, RIF, and MERO  RIF experimental arms are not displayed and did not reduce bacterial counts at 4, 8, or 24 h.
dChange from 0 h bacterial concentration in time-kill experiments [log10(CFUxh)  log10(CFU0h)], where x  4, 8, or 24 h; mean starting inoculum, 8.19  0.07 log10
CFU/ml.
eData from synergistic combinations (defined as those resulting in a 2 log10 CFU/ml mean reduction in viable counts over the results seen with the most active
agent administered alone) are bolded; bacterial reductions for combinations whose results were significantly different from those seen with the most active agent
alone are denoted with an asterisk (P  0.05).
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performed for detection of mutations in K. pneumoniae outer membrane porin
genes ompK35 and ompK36, as described previously (19). KPC-Kp 9A, KPC-Kp 24A,
and KPC-Kp 27A were used in time-kill experiments at an 108 CFU/ml inoculum to
initially assess the combinatorial pharmacodynamics over 24 h, as described pre-
viously (20). Time-kill experiments were carried out in duplicate with polymyxin B
(2.41 and 6 mg/liter) (21), meropenem (49.6 mg/liter) (22), and rifampin (3.5
mg/liter) (23, 24) at concentrations representing the HFIM projected maximum free
drug concentration (fCmax). The lower limit of quantification was 102 CFU/ml.
To build upon the time-kill data, HFIM experiments (cartridge C3008; FiberCell
Systems Inc., Frederick, MD) were performed over 10 days, as previously described (7),
to evaluate the effectiveness of dosing regimens of polymyxin B alone or combined
with meropenem and rifampin. KPC-Kp 9A and KPC-Kp 27A were selected as represen-
tative isolates to use in the HFIM at an 108 CFU/ml inoculum for a proof-of-concept
evaluation of the drug regimens described below. Population analysis profiles (PAPs)
were also determined during the HFIM by plating a 50-l aliquot of a bacterial sample
onto an agar plate embedded with polymyxin B (0.5, 1, 4, or 10 mg/liter) or meropenem
(4, 16, or 64 mg/liter) to simultaneously track the polymyxin- and meropenem-
heteroresistant subpopulations that are often present in K. pneumoniae (25, 26). HFIM
polymyxin B dosage regimens were based on the population pharmacokinetic model
described by Sandri et al. from 24 critically ill patients who received intravenous
polymyxin B doses ranging from 0.45 to 3.38 mg/kg of body weight/day (7, 21). The
following polymyxin B (half-life [t1/2]  8 h), meropenem (t1/2  2.5 h), and rifampin
(t1/2  2.5 h) regimens were simulated using each drug alone or in double or triple
combinations in the HFIM based on human pharmacokinetic data in critically ill patients
(22–24):
i. Polymyxin B loading dose: 2.22 mg/kg for 1 dose followed by 1.43 mg/kg q12h
starting 12 h later, with an fCmax  2.41 mg/liter and area under the
concentration-time curve for the free, unbound fraction of a drug at 24 h
(fAUC24)  35.9 mg · h/liter across every day.
ii. Polymyxin B burst: 5.53 mg/kg for 1 dose followed by no subsequent doses with
an fCmax  6.0 mg/liter and fAUC0–24  60.4 mg · h/liter.
iii. Meropenem: 2 g q8h with an fCmax  48.9 mg/liter and fAUC0–24  657.7 mg ·
h/liter across the first day and an fCmax  49.0 mg/liter and fAUC24  707.3 mg ·
h/liter at the steady state.
iv. Rifampin: 600 mg q24h with an fCmax  3.5 mg/liter and fAUC24  14.0 mg ·
h/liter across every day.
During combination experiments where the HFIM system was set to a 2.5-h half-life,
polymyxin B was supplemented into the central reservoir every 80 min to maintain a
pharmacokinetic profile consistent with an 8-h half-life (27). Samples for validation of
the antimicrobial pharmacokinetics were obtained from monotherapy HFIM runs over
a 48-h period prior to the addition of bacteria. Polymyxin B concentrations were
determined by a liquid chromatography single-quadrupole mass spectrometry (LC-MS)
method (28). Meropenem concentrations were quantified using a liquid chromatogra-
phy tandem mass spectrometry method (LC-MS/MS) that utilized an Agilent 1200
system and an Agilent 6430 system (Santa Clara, CA) (29). Rifampin concentrations were
validated using a microbiological assay that utilized Staphylococcus aureus (ATCC
29213) as an indicator organism embedded in Mueller-Hinton agar (MHA) at 107
CFU/ml (30). Using 35 ml of agar, rifampin concentrations ranging from 0.0625 to 10
mg/liter were used to generate a logarithmic standard curve (R2  0.99). There was
satisfactory agreement between the observed and targeted pharmacokinetic profiles
for polymyxin B (R2  0.98, slope  0.83, and intercept  0.10), meropenem (R2 
0.97, slope  0.85, and intercept  1.67), and rifampin (R2  0.99, slope  1.15, and
intercept  0.08).
In time-kill experiments against KPC-Kp 9A, KPC-Kp 24A, and KPC-Kp 27A, mono-
therapies were unable to sustain bacterial killing through 24 h (Table 1). A double
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combination with polymyxin B at 6 mg/liter and rifampin was bactericidal (3 log10
CFU/ml reduction in viable colony count from the initial inoculum) and synergistic at
24 h against all three isolates, whereas polymyxin B at 6 mg/liter combined with
meropenem was bactericidal and synergistic only against isolate KPC-Kp 27A at 24 h.
Triple combination therapy with polymyxin B at 6 mg/liter yielded synergistic killing
and undetectable bacterial counts at 24 h against all isolates.
In the HFIM, neither meropenem nor rifampin as monotherapy was able to cause
bacterial killing of KPC-Kp 9A at any time point (Fig. 1). Polymyxin B monotherapy
administered as either a loading dose or a burst regimen caused 3 log10 CFU/ml
bacterial reductions throughout the first 6 h. The polymyxin B loading dose achieved
bactericidal activity and a maximal bacterial reduction of 3.57 log10 CFU/ml after 3 h,
while the burst regimen provided bactericidal activity within 2 h and a maximal
bacterial reduction of 5.56 log10 CFU/ml at 4 h. Bacterial killing with each polymyxin B
monotherapy regimen was not maintained, and the total population regrew to growth
control levels by 24 h. The polymyxin B burst regimen, which displayed greater killing
than the loading dose, was essentially unaided by the addition of meropenem, where
maximal log10 CFU/ml reductions of 5.41 were also achieved after 4 h. However, the
addition of rifampin to the polymyxin B burst regimen enabled prolonged killing with
bactericidal activity detected out to 30 h and synergy from 24 to 30 h before the total
population began to regrow.
Triple antimicrobial therapy combining polymyxin B, meropenem, and rifampin
against KPC-Kp 9A in the HFIM substantially potentiated the activity of the individual
agents. This triple combination using a polymyxin B loading dose maintained bacteri-
cidal activity until 54 h (3.81 log10 CFU/ml reduction) and doubled the time during
which the combination could prevent bacterial regrowth compared to polymyxin B
with rifampin. Despite administration of only a single polymyxin B dose, the burst in
combination with meropenem and rifampin displayed the most bacterial killing of
any regimen by tripling the time to bacterial regrowth over two-antibiotic combi-
nations and causing maximal reductions of 5.16 log10 CFU/ml after 78 h. Against
KPC-Kp 27A in the HFIM, the triple combination using a polymyxin B burst caused
a 3.05 log10 CFU/ml reduction by 2 h and a maximal reduction of 6.95 log10 CFU/ml
by 6 h. The triple combination maintained bactericidal activity through at least 30 h
before the bacterial population completely regrew to the level seen with the
growth control by 72 h.
The levels of growth of KPC-Kp 9A and KPC-Kp 27A subpopulations resistant to
polymyxin B and meropenem were tracked using PAPs over 240 h in the HFIM (Fig. 2).
Irrespective of the administered antibiotic regimen, meropenem PAPs remained pro-
portional to that seen with the growth control; there was not an appreciable expansion
of any meropenem subpopulation, even after exposure to meropenem. Growth on
plates containing polymyxin B at up to 10 mg/liter was noted for KPC-Kp 9A after
exposure to polymyxin B without rifampin, including exposure to the burst and
loading-dose monotherapies and the burst plus meropenem combination. In agree-
ment with the PAPs, the KPC-Kp polymyxin B MICs following 240 h of exposure to these
three antimicrobial regimens in the HFIM were 32 mg/liter. Conversely, when poly-
myxin B was administered as a burst in combination with rifampin against KPC-Kp 9A
or KPC-Kp 27A, polymyxin B-resistant subpopulations displayed growth profiles similar
to that of the growth control and, at 240 h postexposure, polymyxin B MICs remained
0.5 mg/liter. Further, the polymyxin B burst, meropenem, and rifampin triple combi-
nation suppressed the polymyxin B- and meropenem-resistant subpopulations to
below baseline levels until at least 96 h for KPC-Kp 9A and 48 h for KPC-Kp 27A. In
comparison to the polymyxin B burst triple combination, the three-drug regimen based
on the polymyxin B loading dose caused 3 log10 CFU/ml more growth on plates
treated with 4 or 10 mg/liter polymyxin B at 240 h and resulted in a postexposure
polymyxin B MIC of 32 mg/liter.
Nontraditional combinations involving the polymyxin antibiotics are frequently
employed in the fight against KPC-Kp because therapeutic options are extremely
Bulman et al. Antimicrobial Agents and Chemotherapy
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limited. However, it is unclear how the polymyxins should be dosed, especially when
used in combination with other agents, such as carbapenems and rifampin. In the
present investigation, against KPC-Kp isolates with meropenem MICs of 16 mg/liter
(stop codons at amino acid [aa] 89 of the ompK35 porin gene), administration of
polymyxin B with meropenem 2-drug combinations did not result in consistent bac-
FIG 1 HFIM total bacterial population counts in log10 CFU/ml over 240 h following exposure to
polymyxin B loading dose (2.22 mg/kg for 1 dose followed by 1.43 mg/kg q12h starting 12 h later),
polymyxin B burst (5.53 mg/kg 	 1 dose followed by no subsequent doses), meropenem (2 g q8h), and
rifampin (600 mg q24h). Experiments were conducted at a starting inoculum of 108 CFU/ml for KPC-Kp
9A versus monotherapies (A), KPC-Kp 9A versus combination therapies (B), and KPC-Kp 27A versus
combination therapy (C).
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terial killing. Unlike KPC-Kp 9A and KPC-Kp 24A, which harbored wild-type ompK36
genes, KPC-Kp 27A had an IS5 insertion in the promoter region of ompK36. Interestingly,
synergy for the polymyxin B and meropenem combination was detected only against
KPC-Kp 27A. The variations in meropenem MICs observed between KPC-Kp 9A, 24A,
and 27A were likely due to these differing combinations of porin channel mutations in
addition to fluctuations in expression of porin channels and the KPC-2 enzyme (31, 32).
Similarly to polymyxin B with meropenem, polymyxin B and rifampin 2-drug combi-
nations caused undetectable counts of only one KPC-Kp strain (isolate 24A) through 24
h; therefore, 3-drug regimens with rifampin were explored.
The addition of rifampin to polymyxin B and meropenem may enable prolonged
bactericidal activity and may improve upon the potentially unreliable activity of 2-drug
combinations against KPC-Kp with higher meropenem MICs. Administration of a poly-
myxin with a carbapenem and rifampin is a promising combination that was previously
shown to be bactericidal (against 8/9 strains) in static time-kill experiments against
FIG 2 Population analysis profiles quantifying the growth of resistant KPC-Kp 9A (A to J) and KPC-Kp 27A (K to L) subpopulations on MHA plates containing
the specified concentration of either polymyxin B (blue lines) or meropenem (red lines). Each panel represents a single antibiotic treatment regimen over 240
h in the HFIM and compares data from the antibiotic-resistant subpopulations, which are fractions of the respective total population (black lines). The black
lines are displayed for comparison and represent the total population bacterial counts from Fig. 1 at time points when population analysis profiles were
simultaneously performed (0, 24, 48, 72, 96, 144, 192, and 240 h). KPC-Kp 9A and KPC-Kp 27A polymyxin B MICs were initially 0.5 and 1 mg/liter, respectively.
Polymyxin B MICs at the end of each experiment, following exposure for 240 h in the HFIM, were 0.5 mg/liter (A),32 mg/liter (B),32 mg/liter (C), 0.5 mg/liter
(D), 0.5 mg/liter (E), 32 mg/liter (F), 0.5 mg/liter (G), 0.5 mg/liter (H), 32 mg/liter (I), 0.5 mg/liter (J), 0.5 mg/liter (K), and 0.5 mg/liter (L). KPC-Kp 9A and KPC-Kp
27A remained polymyxin susceptible following exposure to all combinations containing a polymyxin B burst plus rifampin.
Bulman et al. Antimicrobial Agents and Chemotherapy
April 2017 Volume 61 Issue 4 e02023-16 aac.asm.org 6
carbapenemase-producing K. pneumoniae (33, 34) and was further validated in the
present study. In the current investigation, rifampin added to a polymyxin B burst
preserved polymyxin susceptibility through 10 days (polymyxin B MIC240 h  0.5
mg/liter) for both KPC-Kp isolates. Contrastingly, polymyxin B monotherapy or poly-
myxin B plus meropenem or traditionally dosed polymyxin B plus meropenem and
rifampin regimens resulted in amplified polymyxin resistance where KPC-Kp polymyxin
B MICs were 32 mg/liter at 10 days postexposure. The benefit of coadministration of
rifampin with the polymyxin B burst and meropenem may be multifactorial as a
consequence of (i) directly reducing K. pneumoniae total population counts and (ii)
suppressing polymyxin B resistance. Recurrent 1 to 2 log10 CFU/ml drops in bacterial
density seen during administration of a polymyxin B-rifampin combination, but not
rifampin monotherapy, in the HFIM support the concept that killing caused by rifampin
is potentiated by polymyxin B, possibly via damage to the outer membrane of K.
pneumoniae (35). Suppression of polymyxin B resistance by rifampin could be explained
by an ability to inhibit the expression of lipopolysaccharide regulators such as phoP
plus phoQ and pmrA plus pmrB, which can lower the negative charge of the K.
pneumoniae outer membrane, thus decreasing polymyxin affinity (35). These two-
component regulatory systems have also been shown to play an important clinical role
in K. pneumoniae polymyxin heteroresistance, making them an enticing target for
suppression (36).
Previous dynamic in vitro experiments (HFIM and one-compartment model) exam-
ining regimens against KPC-Kp have not described pharmacodynamic activity past 72 h
(13, 37–40). Therefore, it is remarkable that in the present study, the triple combination
that included a polymyxin B burst, meropenem, and rifampin was bactericidal until at
least 78 h for KPC-Kp 9A and 30 h for KPC-Kp 27A despite combatting a starting
inoculum that was 10 to 1,000	 higher than those previously investigated. The use of
KPC-Kp at an inoculum of 108 CFU/ml was employed to simulate the potentially high
bacterial densities in deep-seated infections. In the context of infections with a lower
bacterial burden, such as urinary tract infections and bacteremia, our results may
underestimate the activity of the individual antibiotics (41). Our study should be
examined in concert with the other studies that have explored combinations against
KPC-Kp at lower inocula.
Polymyxin nephrotoxicity is the most clinically significant dose-limiting adverse
event (42). Administration of a large one-time polymyxin B dose holds significant
promise to circumvent cumulative drug exposure concerns which have been predictive
of polymyxin-induced nephrotoxicity (43, 44). Remarkably, the triple combination
incorporating the polymyxin B burst regimen displayed enhanced bacterial killing
compared to the more traditional loading-dose-based combination, despite a cumula-
tive polymyxin B exposure (AUC0–240) of 20% over 10 days. Furthermore, during
exposure to polymyxin B burst-based combinations with rifampin, the K. pneumoniae
isolates remained polymyxin B susceptible and there were fewer polymyxin B-resistant
subpopulations present despite regrowth.
There are a number of important things to consider while interpreting the data
contained in the present manuscript. One limitation of the time-kill experiments is that
static fCmax concentrations were used, which may in part explain the greater killing that
was observed compared to the HFIM. Polymyxin B, meropenem, and rifampin were
simulated in the HFIM to approximate human pharmacokinetics in critically ill patients.
However, there is likely significant interpatient variability that exists for the pharma-
cokinetics of these drugs in the clinical setting, which may influence the translation of
these findings. Lastly, the polymyxin B burst, meropenem, and rifampin triple combi-
nation was tested only against 2 KPC-Kp isolates in the HFIM and its activity should be
further validated in other clinically relevant strains.
In conclusion, the promising combination of polymyxin B, meropenem, and rifampin
appears to provide a viable option to consider in the treatment of KPC-Kp, including
against isolates with higher carbapenem MICs. Importantly, in combination with poly-
myxin B, rifampin seems to enable temporary suppression of polymyxin B resistance
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while acting to directly kill the K. pneumoniae strain, suggesting a multifactorial mode
of attack. Further investigations in vitro and using animal models are warranted before
translation to the clinic.
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